drugset
drugset / Trial / NCT04987333

Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants

NCT04987333 ↗

Phase 1 Completed 32 enrolled Amgen
Non-randomizedSequentialOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the pharmacokinetics (PK) of efavaleukin alfa after single subcutaneous (SC) administration in healthy Chinese, Japanese, and Caucasian participants.

Timeline

Start
2021-08-09
Primary completion
2022-10-03
Completion
2022-10-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavaleukin alfa Protein / enzyme biologic — Subcutaneous

Indications

inflammatory disease